Gene-delivered butyrylcholinesterase is prophylactic against the toxicity of chemical warfare nerve agents and organophosphorus compounds

Journal of Pharmacology and Experimental Therapeutics

Volumn 337, Issue 1, 2011, Pages 92-101

  Parikh, Kalpana ^b   Duysen, Ellen G ^c   Snow, Benjamin ^b   Jensen, Neil S ^a   Manne, Veeraswamy ^a   Lockridge, Oksana ^c   Chilukuri, Nageswararao ^a  

^a US ARMY MEDICAL RESEARCH INSTITUTE OF CHEMICAL DEFENSE   (United States)

^b WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^c UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; CHEMICAL WARFARE AGENT; CHOLINESTERASE; ECOTHIOPATE; METHYLPHOSPHONOTHIOIC ACID S (2 DIISOPROPYLAMINOETHYL) O ETHYL ESTER;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL STRAIN HEK293; CONTROLLED STUDY; DRUG BLOOD LEVEL; ENZYME ACTIVITY; FEMALE; LD 50; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROPHYLAXIS; PROTECTION; TOXICITY; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

ADENOVIRIDAE; ANIMALS; BUTYRYLCHOLINESTERASE; CHEMICAL WARFARE AGENTS; FEMALE; GENE TRANSFER TECHNIQUES; HEK293 CELLS; HUMANS; MICE; MICE, 129 STRAIN; MICE, KNOCKOUT; ORGANOPHOSPHORUS COMPOUNDS;

EID: 79953004602     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.110.175646     Document Type: Article

References (40)

1. Ashani Y and Pistinner S (2004) Estimation of the upper limit of human butyrylcholinesterase dose required for protection against organophosphates toxicity: a mathematically based toxicokinetic model. Toxicol Sci 77:358-367. (Pubitemid 38262609)
2. Bird SB, Dawson A, and Ollis D (2010) Enzymes and bioscavengers for prophylaxis and treatment of organophosphate poisoning. Front Biosci (Schol Ed) 2:209-220.
3. Broomfield CA, Maxwell DM, Solana RP, Castro CA, Finger AV, and Lenz DE (1991) Protection by butyrylcholinesterase against organophosphorus poisoning in nonhuman primates. J Pharmacol Exp Ther 259:633-638.
4. Cerasoli DM, Griffiths EM, Doctor BP, Saxena A, Fedorko JM, Greig NH, Yu QS, Huang Y, Wilgus H, Karatzas CN, et al. (2005) In vitro and in vivo characterization of recombinant human butyrylcholinesterase (Protexia) as a potential nerve agent bioscavenger. Chem Biol Interact 157-158:363-365.
5. Chilukuri N, Duysen EG, Parikh K, diTargiani R, Doctor BP, Lockridge O, and Saxena A (2009) Adenovirus-transduced human butyrylcholinesterase in mouse blood functions as a bioscavenger of chemical warfare nerve agents. Mol Pharmacol 76:612-617.
6. Chilukuri N, Duysen EG, Parikh K, Sun W, Doctor BP, Lockridge O, and Saxena A (2008a) Adenovirus-mediated gene transfer of human butyrylcholinesterase results in persistent high-level transgene expression in vivo. Chem Biol Interact 175:327-331.
7. Chilukuri N, Parikh K, Sun W, Naik R, Tipparaju P, Doctor BP and Saxena A (2005) Polyethylene glycosylation prolongs the circulatory stability of recombinant human butyrylcholinesterase. Chem Biol Interact 157-158:115-121. (Pubitemid 41757641)
8. Chilukuri N, Sun W, Naik RS, Parikh K, Tang L, Doctor BP, and Saxena A (2008b) Effect of polyethylene glycol modification on the circulatory stability and immunogenicity of recombinant human butyrylcholinesterase. Chem Biol Interact 175:255-260.
9. Cléry-Barraud C, Renault F, Leva J, El Bakdouri N, Masson P, and Rochu D (2009) Exploring the structural and functional stabilities of different paraoxonase-1 formulations through electrophoretic mobilities and enzyme activity parameters under hydrostatic pressure. Biochim Biophys Acta 1794:680-688.
10. Dai Y, Schwarz EM, Gu D, Zhang WW, Sarvetnick N, and Verma IM (1995) Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: tolerization of factor IX and vector antigens allows for long-term expression. Proc Natl Acad Sci USA 92:1401-1405.
11. Doctor BP, Toker L, Roth E, and Silman I (1987) Microtiter assay for acetylcholinesterase. Anal Biochem 166:399-403. (Pubitemid 18004908)
12. Duysen EG, Bartels CF, and Lockridge O (2002) Wild-type and A328W mutant human butyrylcholinesterase tetramers expressed in Chinese hamster ovary cells have a 16-hour half-life in the circulation and protect mice from cocaine toxicity. J Pharmacol Exp Ther 302:751-758. (Pubitemid 34787244)
13. Ellman GL, Courtney KD, Andres V Jr, and Feather-Stone RM (1961) A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 7:88-95.
14. Gao Y, Atanasova E, Sui N, Pancook JD, Watkins JD, and Brimijoin S (2005) Gene transfer of cocaine hydrolase suppresses cardiovascular responses to cocaine in rats. Mol Pharmacol 67:204-211. (Pubitemid 40069980)
15. Gao Y and Brimijoin S (2009) Lasting reduction of cocaine action in neostriatum - a hydrolase gene therapy approach. J Pharmacol Exp Ther 330:449-457.
16. Geyer BC, Kannan L, Cherni I, Woods RR, Soreq H, and Mor TS (2010) Transgenic plants as a source for the bioscavenging enzyme, human butyrylcholinesterase. Plant Biotechnol J 8:873-886.
17. Hrabovska A, Bernard V, and Krejci E (2010) A novel system for the efficient generation of antibodies following immunization of unique knockout mouse strains. PLoS One 5:e12892.
18. Huang YJ, Huang Y, Baldassarre H, Wang B, Lazaris A, Leduc M, Bilodeau AS, Bellemare A, Côté M, Herskovits P, et al. (2007) Recombinant human butyrylcholinesterase from milk of transgenic animals to protect against organophosphate poisoning. Proc Natl Acad Sci USA 104:13603-13608. (Pubitemid 350010655)
19. Imperiale MJ and Kochanek S (2004) Adenovirus vectors: biology, design, and production. Curr Top Microbiol Immunol 273:335-357.
20. Karnovsky MJ and Roots L (1964) A "direct-coloring" thiocholine method for cholinesterases. J Histochem Cytochem 12:219-221.
21. Lenz DE, Broomfield CA, Yeung DT, Masson P, Maxwell DM and Cerasoli DM (2007a) Nerve agent bioscavengers: Progress in development of a new mode of protection against organophosphorus exposure, in Chemical Warfare Agents Chemistry, Pharmacology, Toxicology and Therapeutics (Romano JA, Lukey BJ, and Salem H eds) pp 175-202, CRC Press, Boca Raton, FL.
22. Lenz DE, Maxwell DM, Koplovitz I, Clark CR, Capacio BR, Cerasoli DM, Federko JM, Luo C, Saxena A, Doctor BP, et al. (2005) Protection against soman or VX poisoning by human butyrylcholinesterase in guinea pigs and cynomolgus monkeys. Chem Biol Interact 157-158:205-210. (Pubitemid 41757652)
23. Lenz DE, Yeung D, Smith JR, Sweeney RE, Lumley LA, and Cerasoli DM (2007b) Stoichiometric and catalytic scavengers as protection against nerve agent toxicity: a mini review. Toxicology 233:31-39. (Pubitemid 46505351)
24. Li B, Duysen EG, Carlson M, and Lockridge O (2008a) The butyrylcholinesterase knockout mouse as a model for human butyrylcholinesterase deficiency. J Pharmacol Exp Ther 324:1146-1154. (Pubitemid 351397863)
25. Li B, Duysen EG, Saunders TL, and Lockridge O (2006) Production of the butyrylcholinesterase knockout mouse. J Mol Neurosci 30:193-195.
26. Li B, Sedlacek M, Manoharan I, Boopathy R, Duysen EG, Masson P, and Lockridge O (2005) Butyrylcholinesterase, paraoxonase, and albumin esterase, but not carboxylesterase, are present in human plasma. Biochem Pharmacol 70:1673-1684. (Pubitemid 41540360)
27. Li H, Schopfer LM, Masson P, and Lockridge O (2008b) Lamellipodin proline rich peptides associated with native plasma butyrylcholinesterase tetramers. Biochem J 411:425-432. (Pubitemid 351580195)
28. Li S, Ip DT, Lin HQ, Liu JM, Miao YG, Ke LJ, and Wan DC (2010) High-level expression of functional recombinant human butyrylcholinesterase in silkworm larvae by Bac-to-Bac system. Chem Biol Interact 187:101-105.
29. Masson P and Lockridge O (2010) Butyrylcholinesterase for protection from organophosphorus poisons: catalytic complexities and hysteretic behavior. Arch Biochem Biophys 494:107-120.
30. Maxwell DM and Brecht KM (2001) Carboxylesterase: specificity and spontaneous reactivation of an endogenous scavenger for organophosphorus compounds. J Appl Toxicol 21(Suppl 1):S103-S107.
31. Raveh L, Grauer E, Grunwald J, Cohen E, and Ashani Y (1997) The stoichiometry of protection against soman and VX toxicity in monkeys pretreated with human butyrylcholinesterase. Toxicol Appl Pharmacol 145:43-53. (Pubitemid 27294768)
32. Raveh L, Grunwald J, Marcus D, Papier Y, Cohen E, and Ashani Y (1993) Human butyrylcholinesterase as a general prophylactic antidote for nerve agent toxicity. In vitro and in vivo quantitative characterization. Biochem Pharmacol 45:2465-2474.
33. Rosenberg Y, Luo C, Ashani Y, Doctor BP, Fischer R, Wolfe G, and Saxena A (2002) Pharmacokinetics and immunologic consequences of exposing macaques to purified homologous butyrylcholinesterase. Life Sci 72:125-134.
34. Ryhänen RJ (1983) Pseudocholinesterase activity in some human body fluids. Gen Pharmacol 14:459-460.
35. Saxena A, Sun W, Luo C and Doctor BP (2005) Human serum butyrylcholinesterase: in vitro and in vivo stability, pharmacokinetics, and safety in mice. Chem Biol Interact 157-158:199-203. (Pubitemid 41757651)
36. Saxena A, Sun W, Luo C, Myers TM, Koplovitz I, Lenz DE, and Doctor BP (2006) Bioscavenger for protection from toxicity of organophosphorus compounds. J Mol Neurosci 30:145-148.
37. Sun H, Pang YP, Lockridge O, and Brimijoin S (2002) Re-engineering butyrylcholinesterase as a cocaine hydrolase. Mol Pharmacol 62:220-224. (Pubitemid 34804100)
38. Wei WL, Qin JC, and Sun MJ (2000) High-level expression of human butyrylcholinesterase gene in Bombyx mori and biochemical-pharmacological characteristic study of its product. Biochem Pharmacol 60:121-126.
39. Wolfe AD, Blick DW, Murphy MR, Miller SA, Gentry MK, Hartgraves SL, and Doctor BP (1992) Use of cholinesterases as pretreatment drugs for the protection of rhesus monkeys against soman toxicity. Toxicol Appl Pharmacol 117:189-193. (Pubitemid 23009714)
40. Yang Y, Li Q, Ertl HC, and Wilson JM (1995) Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses. J Virol 69:2004-2015.